International cancer seminars: a focus on kidney cancer

G Scelo¹, J N Hofmann², R E Banks³, P Bigot⁴, R S Bhatt⁵, G Cancel-Tassin⁶, S K Chew⁷, C J Creighton⁸, O Cussenot⁶, I J Davis⁹, B Escudier¹⁰, T M Frayling¹¹, C Häggström¹², M A T Hildebrandt¹³, I Holcatova¹⁴, M Johansson¹, W M Linehan¹⁵, D F McDermott⁵, K L Nathanson¹⁶, S Ogawa¹⁷, E J Perlman¹⁸, M P Purdue², P Stattin¹⁹, C Swanton²⁰, N S Vasudev³, X Wu²¹, A Znaor¹, P Brennan²², S J Chanock²³

Affiliations

¹ Section of Genetics, International Agency for Research on Cancer, Lyon, France.
² Division of Cancer Epidemiology and Genetics, Department of Health and Human Service, National Cancer Institute, National Institutes of Health, Bethesda, USA.
³ Clinical and Biomedical Proteomics Group, Cancer Research UK Centre, Leeds Institute for Cancer Studies and Pathology, St James' University Hospital, Leeds, UK.
⁴ Department of Urology, Centre Hospitalier Universitaire d'Angers, Angers, France.
⁵ Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Kidney Cancer Program, Dana-Farber/Harvard Cancer Center, Boston, MA, USA.
⁶ Groupe de Recherche GRC-UPMC n°5, Centre de Recherche sur les Pathologies Prostatiques et Urologiques (CeRePP), Paris, France.
⁷ Translational Cancer Therapeutics Laboratory, UCL Cancer Institute, University College London, London, UK.
⁸ Duncan Cancer Center-Biostatistics, Baylor College of Medicine, Houston.
⁹ Department of Genetics, UNC School of Medicine, Chapel Hill, USA.
¹⁰ Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.
¹¹ University of Exeter Medical School, Exeter, UK.
¹² Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå Department of Biobank Research, Umeå University, Umeå, Sweden.
¹³ Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, USA.
¹⁴ Institute of Public Health and Preventive Medicine, Charles University, 2nd Faculty of Medicine, Prague, Czech Republic.
¹⁵ Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda.
¹⁶ Department of Medicine, University of Pennsylvania, Philadelphia, USA.
¹⁷ Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
¹⁸ Department of Pathology, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, USA.
¹⁹ Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå
²⁰ University College London Hospitals and Cancer Institute, London, UK.
²¹ Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, USA.
²² Section of Genetics, International Agency for Research on Cancer, Lyon, France brennanp@iarc.fr.
²³ Division of Cancer Epidemiology and Genetics, Department of Health and Human Service, National Cancer Institute, National Institutes of Health, Bethesda, USA brennanp@iarc.fr.

PMID: 27130845
PMCID: PMC4959923
DOI: 10.1093/annonc/mdw186

International cancer seminars: a focus on kidney cancer

G Scelo et al. Ann Oncol. 2016 Aug.

. 2016 Aug;27(8):1382-5.

doi: 10.1093/annonc/mdw186. Epub 2016 Apr 29.

Authors

Affiliations

¹ Section of Genetics, International Agency for Research on Cancer, Lyon, France.
² Division of Cancer Epidemiology and Genetics, Department of Health and Human Service, National Cancer Institute, National Institutes of Health, Bethesda, USA.
³ Clinical and Biomedical Proteomics Group, Cancer Research UK Centre, Leeds Institute for Cancer Studies and Pathology, St James' University Hospital, Leeds, UK.
⁴ Department of Urology, Centre Hospitalier Universitaire d'Angers, Angers, France.
⁵ Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Kidney Cancer Program, Dana-Farber/Harvard Cancer Center, Boston, MA, USA.
⁶ Groupe de Recherche GRC-UPMC n°5, Centre de Recherche sur les Pathologies Prostatiques et Urologiques (CeRePP), Paris, France.
⁷ Translational Cancer Therapeutics Laboratory, UCL Cancer Institute, University College London, London, UK.
⁸ Duncan Cancer Center-Biostatistics, Baylor College of Medicine, Houston.
⁹ Department of Genetics, UNC School of Medicine, Chapel Hill, USA.
¹⁰ Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.
¹¹ University of Exeter Medical School, Exeter, UK.
¹² Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå Department of Biobank Research, Umeå University, Umeå, Sweden.
¹³ Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, USA.
¹⁴ Institute of Public Health and Preventive Medicine, Charles University, 2nd Faculty of Medicine, Prague, Czech Republic.
¹⁵ Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda.
¹⁶ Department of Medicine, University of Pennsylvania, Philadelphia, USA.
¹⁷ Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
¹⁸ Department of Pathology, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, USA.
¹⁹ Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå
²⁰ University College London Hospitals and Cancer Institute, London, UK.
²¹ Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, USA.
²² Section of Genetics, International Agency for Research on Cancer, Lyon, France brennanp@iarc.fr.
²³ Division of Cancer Epidemiology and Genetics, Department of Health and Human Service, National Cancer Institute, National Institutes of Health, Bethesda, USA brennanp@iarc.fr.

PMID: 27130845
PMCID: PMC4959923
DOI: 10.1093/annonc/mdw186

Abstract

Recent years have seen important advances in our understanding of the etiology, biology and genetics of kidney cancer. To summarize important achievements and identify prominent research questions that remain, a workshop was organized by IARC and the US NCI. A series of 'difficult questions' were formulated, which should be given future priority in the areas of population, genomic and clinical research.

Keywords: clinical research; epidemiology; genomics; kidney cancer.

PubMed Disclaimer

Comment in

Where next in kidney cancer?
Powles T. Powles T. Ann Oncol. 2016 Aug;27(8):1376-7. doi: 10.1093/annonc/mdw247. Ann Oncol. 2016. PMID: 27457307 No abstract available.

References

1. Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A, Bray F. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol 2015; 67(3): 519–530. - PubMed
1. Li P, Znaor A, Holcatova I et al. Regional geographic variations in kidney cancer incidence rates in European countries. Eur Urol 2015; 67(6): 1134–1141. - PubMed
1. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol 2010; 7(5): 245–257. - PMC - PubMed
1. Haas NB, Nathanson KL. Hereditary kidney cancer syndromes. Adv Chronic Kidney Dis 2014; 21(1): 81–90. - PMC - PubMed
1. Linehan WM. Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. Genome Res 2012; 22(11): 2089–2100. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

International cancer seminars: a focus on kidney cancer

Affiliations

International cancer seminars: a focus on kidney cancer

Authors

Affiliations

Abstract

Comment in

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical